Five-Year Outcomes of a Phase 1 Dose-Escalation Study Using Stereotactic Body Radiosurgery for Patients With Low-Risk and Intermediate-Risk Prostate Cancer-Reference-Cited by-同舟云学术

Five-Year Outcomes of a Phase 1 Dose-Escalation Study Using Stereotactic Body Radiosurgery for Patients With Low-Risk and Intermediate-Risk Prostate Cancer

Published:2019-05 Issue:1 Volume:104 Page:42-49
ISSN:0360-3016
Container-title:International Journal of Radiation Oncology*Biology*Physics
language:en
Short-container-title:International Journal of Radiation Oncology*Biology*Physics

Author:

Zelefsky Michael J.,Kollmeier Marisa,McBride Sean,Varghese Melissa,Mychalczak Borys,Gewanter Richard,Garg Madhur K.,Happersett Laura,Goldman Debra A.,Pei Isaac,Lin Mary,Zhang Zhigang,Cox Brett W.

Funder

Cancer Center Support

National Cancer Institute

National Institutes of Health

Publisher

Elsevier BV

Subject

Cancer Research,Radiology Nuclear Medicine and imaging,Oncology,Radiation

Reference15 articles.

1. Stereotactic body radiotherapy for localized prostate cancer: Pooled analysis from a multi-institutional consortium of prospective phase II trials;King;Radiother Oncol,2013

2. Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer;King;Int J Radiat Oncol Biol Phys,2012

3. Stereotactic body radiotherapy for low-risk prostate cancer: A 10-year analysis;Katz;Cureus,2017